Company facts
- Headquarters
- South San Francisco, California
- Most recent report
- 8-K, filed Oct 26, 2026
- Incorporated
- Delaware
- Filings on record
- 40 filings
- On EDGAR
- CIK 1806540
- Fiscal year ends
- December
- Filer status
- N/A
News 1
Prospectuses and Registrations 4
Ownership 8 of 25
- 4 Insider reported a trade Nov 4, 2026
- SCHEDULE 13G Large holder reported a passive stake Oct 30, 2026
- 4 Insider reported a trade Oct 30, 2026
- 4 Insider reported a trade Oct 28, 2026
- 4 Insider reported a trade Oct 27, 2026
- 4 Insider reported a trade Oct 26, 2026
- 4 Insider reported a trade Oct 26, 2026
- 4 Insider reported a trade Oct 26, 2026
Other 8 of 10
- EFFECT Notice that a registration became effective Oct 22, 2026
- S-1MEF Oct 22, 2026
- CERT Exchange certified a listing Oct 22, 2026
- 8-A12B Registration of a security for exchange listing Oct 20, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Aug 27, 2026
- DRS Draft registration statement, submitted confidentially Jul 2, 2026
- D Jun 25, 2026
- D May 23, 2024
Everything here comes from Lycia Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.